Research
CFTR mutations that are responsive to elexacaftor/tezacaftor/ivacaftor were determined by an in-vitro study of Fischer Rat Thyroid (FRT) cells that expressed mutant CFTR. Elexacaftor/tezacaftor/ivacaftor showed effectiveness with mutations where the CFTR protein was being successfully delivered to the cell surface. References
External links
"Elexacaftor". Drug Information Portal. U.S. National Library of Medicine. "Ivacaftor regimen with Tezacaftor". Drug Information Portal. U.S. National Library of Medicine.
Clinical observation is considered when the mass is diagnosed pre-operatively. Surgery is often required to confirm the diagnosis and exclude a mimic of a malignant mass. Surgical approach should attempt to divide the mass and the gonad at the connecting plane for removal of the splenic tissue. Orchiectomy is generally not indicated. Causality between splenogonadal fusion and future malignant transformation has not been established, but literature has highlighted infrequent cases of testicular neoplasms and splenogonadal fusion. These cases were found in patients who also had a history of cryptorchidism, which is a known risk factor for testicular cancer. See also
Splenogonadal fusion-limb defects-micrognathia syndrome


== References ==